μ-opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways

Cellular Signalling

Volumn 24, Issue 8, 2012, Pages 1648-1657

  Cussac, Didier ^a   Rauly Lestienne, Isabelle ^a   Heusler, Peter ^a   Finana, Frédéric ^a   Cathala, Claudie ^a   Bernois, Sophie ^a   De Vries, Luc ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

opioid; 5 HT1A; BRET; G protein; Heterodimer; MAP kinase

Indexed keywords

CALCIUM ION; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT 15; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; RENILLA LUCIFERIN 2 MONOOXYGENASE; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CHEMICAL REACTION; COIMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HETERODIMERIZATION; IMMUNOPRECIPITATION; INTERNALIZATION; NOCICEPTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; DIMERIZATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, OPIOID, MU;

RENILLA LUCIFERASE;

EID: 84861540172     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2012.04.010     Document Type: Article

References (36)

1. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dollé P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Nature 1996, 383:819.
2. Law P.Y., Wong Y.H., Loh H.H. Annual Review of Pharmacology and Toxicology 2000, 40:389.
3. Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P., Murray S.R., Von Zastrow M. Science 2002, 297:615.
4. Finn A.K., Whistler J.L. Neuron 2001, 32:829.
5. Gomes I., Gupta A., Filipovska J., Szeto H.H., Pintar J.E., Devi L.A. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:5135.
6. Jordan B.A., Gomes I., Rios C., Filipovska J., Devi L.A. Molecular Pharmacology 2003, 64:1317.
7. Pfeiffer M., Kirscht S., Stumm R., Koch T., Wu D., Laugsch M., Schroder H., Hollt V., Schulz S. Journal of Biological Chemistry 2003, 278:51630.
8. Milan-Lobo L., Whistler J.L. Journal of Pharmacology and Experimental Therapeutics 2011, 337:868.
9. Gomes I., Ijzerman A.P., Ye K., Maillet E.L., Devi L.A. Molecular Pharmacology 2011, 79:1044.
10. Savitz J., Lucki I., Drevets W.C. Progress in Neurobiology 2009, 88:17.
11. Akimova E., Lanzenberger R., Kasper S. Biological Psychiatry 2009, 66:627.
12. Colpaert F.C., Tarayre J.P., Koek W., Pauwels P.J., Bardin L., Xu X.J., Wiesenfeld-Hallin Z., Cosi C., Carilla-Durand E., Assié M.B., Vacher B. Neuropharmacology 2002, 43:945.
13. Millan M.J., Seguin L., Honoré P., Girardon S., Bervoets K. Behavioural Brain Research 1996, 73:69.
14. Sastre-Coll A., Esteban S., Garcia-Sevilla J.A. Naunyn-Schmiedeberg's Archives of Pharmacology 2002, 365:210.
15. Nayebi A.R., Charkhpour M. Pharmacology Biochemistry and Behavior 2006, 83:203.
16. Lutz P.E., Pradhan A.A., Goeldner C., Kieffer B.L. European Neuropsychopharmacology 2011, 21:835.
17. Pompeiano M., Palacios J.M., Mengod G. Journal of Neuroscience 1992, 12:440.
18. Zhang Y.Q., Gao X., Huang Y.L., Wu G.C. Neuroreport 2000, 11:3361.
19. Wang Q.P., Ochiai H., Guan J.L., Nakai Y. Synapse 1998, 29:240.
20. Daval G., Vergé D., Basbaum A.I., Bourgoin S., Hamon M. Neuroscience Letters 1987, 83:71.
21. Kishimoto K., Koyama S., Akaike N. Neuropharmacology 2001, 41:529.
22. Pauwels P.J., Tardif S., Finana F., Wurch T., Colpaert F.C. Journal of Neurochemistry 2000, 74:375.
23. Pauwels P.J., Tardif S., Wurch T., Colpaert F.C. Naunyn-Schmiedeberg's Archives of Pharmacology 1997, 356:551.
24. Heusler P., Newman-Tancredi A., Loock T., Cussac D. European Journal of Pharmacology 2008, 581:37.
25. Tan M., Walwyn W.M., Evans C.J., Xie C.W. Journal of Biological Chemistry 2009, 284:6270.
26. Milligan G. Trends in Pharmacological Sciences 2000, 21:24.
27. Molinari P., Ambrosio C., Riitano D., Sbraccia M., Gro M.C., Costa T. Journal of Biological Chemistry 2003, 278:15778.
28. Conklin B.R., Farfel Z., Lustig K.D., Julius D., Bourne H.R. Nature 1993, 363:274.
29. Ciruela A., Dixon A.K., Bramwell S., Gonzalez M.I., Pinnock R.D., Lee K. British Journal of Pharmacology 2003, 138:751.
30. Ji R.R., Gereau R.W., Malcangio M., Strichartz G.R. Brain Research Reviews 2009, 60:135.
31. Vilardaga J.P., Nikolaev V.O., Lorenz K., Ferrandon S., Zhuang Z., Lohse M.J. Nature Chemical Biology 2008, 4:126.
32. Morgan D., Picker M.J. Psychopharmacology 1995, 122:336.
33. Bardin L., Tarayre J.P., Malfetes N., Koek W., Colpaert F.C. Pharmacology 2003, 67:182.
34. Colpaert F.C., Deseure K., Stinus L., Adriaensen H. Journal of Pharmacology and Experimental Therapeutics 2006, 316:892.
35. Berge O., Fasmer O.B., Ogren S.O., Hole K. Neuroscience Letters 1985, 54:71.
36. Waldhoer M., Fong J., Jones R.M., Lunzer M.M., Sharma S.K., Kostenis E., Portoghese P.S., Whistler J.L. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9050.